Highmark Marketing Inc.
CNSX : HMK

Highmark Marketing Inc.

September 05, 2014 16:10 ET

Highmark Names Cannabis R&D Division and Enters Into Consulting Agreement

VANCOUVER, BRITISH COLUMBIA--(Marketwired - Sept. 5, 2014) -

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES.

Highmark Marketing Inc. (CSE:HMK) ("Highmark") is pleased to announce that it has named its newly formed cannabis R&D division as MJ Bioscience. Dr. Dmytro P. Yevtushenko is the Head of MJ Bioscience.

Highmark has also entered into a consulting agreement (the "Agreement") with PRC Partners Ltd. ("PRC"). Highmark will pay PRC a fee of $5,000 per month under the Agreement.

Highmark intends to pay $135,000CDN for services rendered through the issuance of 300,000 common shares at a price of $.45 per common share. The common shares issued in connection with this transaction will be subject to a four-month hold period.

About Highmark

Highmark is a nutraceutical company, based in British Columbia, focused on bringing the health benefits of natural and herbal remedies to the market. Highmark intends to acquire, license, distribute, and market products in the nutraceutical industry.

Further information about Highmark is available under its profile on the SEDAR website www.sedar.com and on Highmark's page on the CSE website at www.thecse.com.

The CSE has not reviewed, approved or disapproved the content of this press release.

Forward-Looking Information:

This press release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business of Highmark. Forward-looking information is based on certain key expectations and assumptions made by the management of Highmark, including future plans for acquisitions. Although Highmark believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because Highmark can give no assurance that they will prove to be correct. Forward-looking statements contained in this press release are made as of the date of this press release. Highmark disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

Not an Offer In the United States:

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein in the United States. The securities described herein have not been and will not be registered under the United States Securities Act of 1933, as amended, or any applicable securities laws or any state of the United States and may not be offered or sold in the United States or to the account or benefit of a person in the United States absent an exemption from the registration requirements.

Contact Information